Business
Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer
Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer\n \n \nMarina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer\n \n CITY OF INDUSTRY, CA--(Marketwired - Feb 21, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Seymour Fein, M.D., as Chief Medical Officer\n \"I am thrilled to welcome Dr. Fein to the Marina Biotech team,\" stated Joseph W. Ramelli, CEO of Marina Biotech. \"His strong background and expertise in gastroenterology and oncology, make him the perfect fit to oversee the clinical development of Marina Biotech's pipeline. The fact that he has successfully taken over 20 drugs through development to approval, is a strong endorsement of the potential for the company to successfully develop innovative therapies for horrible diseases such as familial adenomatous polyposis (FAP).\"\n \"I'm excited to join the Marina Biotech team and for the opportunity to help develop CEQ508 for the unmet medical need of FAP. This product is a first in class shRNA which utilizes a novel delivery technology enabling oral administration and direct targeting of the dysplastic tissue,\" stated Dr. Seymour Fein.\n Dr. Fein's professional activities have been focused on drug development research for over 35 years. He has been extensively involved in the successful development of numerous drugs, biologics and medical devices over this time leading to FDA approvals for over 20 drugs (NDAs, sNDAs, BLAs) and devices (PMAs). Dr. Fein began his career at Hoffmann-La Roche Ltd. as a senior research physician and was responsible for a clinical development program that led to U.S. Food and Drug Administration (FDA) approval of recombinant interferon-alpha for cancer treatment. Dr. Fein was also the medical director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for therapeutic areas including gastroenterology, oncology, and cardiology. He later served as medical director for Rorer Group (now part of Sanofi) and Ohmeda (now part of Baxter). Dr. Fein founded and has been managing partner of a clinical and regulatory consulting organization and has worked closely with the Division of Gastroenterology...